FLT3 and acute myeloid leukemia: These findings combined may aid in composing and introducing new treatment approaches for AML patients with FLT3-ITD mutations, in which metabolomics has already been introduced in novel research on gilteritinib32, FLT3-Inhibitor AC220 (quizartinib) and the Complex I Inhibitor IACS-01075933 or analyzing resistance to sorafenib34.